Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TALAPRO-3 talazoparib + enzalutamide versus placebo + enzalutamide in DDR-mutated metastatic castration-sensitive prostate cancer
jRCT2031210098Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- May 2021
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of talazoparib, enzalutamide and Placebo-COD Research Private Ltd in prostate cancer (PCa) (2 arms), sponsored by Pfizer. Primary endpoint: Radiographic progression-free survival. Started May 2021; status: active, not recruiting.
02
Drugs
talazoparibenzalutamidePlacebo-COD Research Private Ltd
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on jRCT2031210098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210098.